TRIAL DETAIL
SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 02/01/2008 |
Age of Trial (yrs) 17.2 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
HSP90 inhibitor |
|||
Strategy: |
Destroy KIT |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
CDR0000590247, NCI-08-C-0091, NCI-P07318 |
|||
Sponsor: |
NCI |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
The development of SNX-5422 has been discontinued because of ocular toxicity seen in animal models and in a phase I study. Clin Cancer Res; 17(21); 1–9. ©2011 AACR. |
|||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
9000 Rockville Pike
|
Bethesda |
MD |
20892 |
USA |